Diabetes & Metabolism Journal

Original Article

Basic Research
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway: Shan-Shan Li, Lu Pan, Zhen-Ye Zhang, Meng-Dan Zhou, Xu-Fei Chen, Ling-Ling Qian, Min Dai, Juan Lu, Zhi-Ming Yu, Shipeng Dang, Ru-Xing Wang; Diabetes Metab J. 2024;48(4):716-729. Published online February 27, 2024; DOI: https://doi.org/10.4093/dmj.2023.0031

5,520 View
279 Download
4 Web of Science
6 Crossref

Background
Diabetes-induced cardiac fibrosis is one of the main mechanisms of diabetic cardiomyopathy. As a common histone methyltransferase, enhancer of zeste homolog 2 (EZH2) has been implicated in fibrosis progression in multiple organs. However, the mechanism of EZH2 in diabetic myocardial fibrosis has not been clarified.
Methods
In the current study, rat and mouse diabetic model were established, the left ventricular function of rat and mouse were evaluated by echocardiography and the fibrosis of rat ventricle was evaluated by Masson staining. Primary rat ventricular fibroblasts were cultured and stimulated with high glucose (HG) in vitro. The expression of histone H3 lysine 27 (H3K27) trimethylation, EZH2, and myocardial fibrosis proteins were assayed.
Results
In STZ-induced diabetic ventricular tissues and HG-induced primary ventricular fibroblasts in vitro, H3K27 trimethylation was increased and the phosphorylation of EZH2 was reduced. Inhibition of EZH2 with GSK126 suppressed the activation, differentiation, and migration of cardiac fibroblasts as well as the overexpression of the fibrotic proteins induced by HG. Mechanical study demonstrated that HG reduced phosphorylation of EZH2 on Thr311 by inactivating AMP-activated protein kinase (AMPK), which transcriptionally inhibited peroxisome proliferator-activated receptor γ (PPAR-γ) expression to promote the fibroblasts activation and differentiation.
Conclusion
Our data revealed an AMPK/EZH2/PPAR-γ signal pathway is involved in HG-induced cardiac fibrosis.

Citations

Citations to this article as recorded by

A Computational Approach to Identify Novel Protein Targets Uncovers New Potential Mechanisms of Action of Mirtazapine S(+) and R(−) Enantiomers in Rett Syndrome
Ottavia Maria Roggero, Nicolò Gualandi, Viviana Ciraci, Vittoria Berutto, Emanuele Carosati, Enrico Tongiorgi
Journal of Neurochemistry.2025;[Epub] CrossRef
ER-α36 prevents high glucose-induced cellular senescence and apoptosis in renal tubular cell
Dehai Yu, Ling Luo, Yu Liang, Huili Zhou, Yinghui Xiao, Xingna An, Yingzhao Wang, Zhonggao Xu, Weixia Sun, Wanning Wang
Frontiers in Endocrinology.2025;[Epub] CrossRef
An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory
Tongyue Yang, Feng Qi, Feng Guo, Mingwei Shao, Yi Song, Gaofei Ren, Zhao Linlin, Guijun Qin, Yanyan Zhao
Molecular Medicine.2024;[Epub] CrossRef
Farrerol Alleviates Diabetic Cardiomyopathy by Regulating AMPK-Mediated Cardiac Lipid Metabolic Pathways in Type 2 Diabetic Rats
Jia Tu, Qiaoling Liu, Huirong Sun, Luzhen Gan
Cell Biochemistry and Biophysics.2024; 82(3): 2427. CrossRef
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway (Diabetes Metab J 2024;48:716-29)
Shan-Shan Li, Lu Pan, Shipeng Dang, Ru-Xing Wang
Diabetes & Metabolism Journal.2024; 48(6): 1181. CrossRef
Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29)
Jooyeop Lee, Joon Ho Moon
Diabetes & Metabolism Journal.2024; 48(6): 1176. CrossRef

Review

Drug/Regimen
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins: Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi; Diabetes Metab J. 2022;46(4):517-532. Published online July 27, 2022; DOI: https://doi.org/10.4093/dmj.2022.0198; Correction in: Diabetes Metab J 2022;46(5):817

17,954 View
1,105 Download
45 Web of Science
45 Crossref

Abstract PDF PubReader ePub

Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) and other atherogenic particles. During the past decade, several drugs have been developed for the treatment of dyslipidemia. Inclisiran, a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to that of PCSK9 monoclonal antibodies. Bempedoic acid, an ATP citrate lyase inhibitor, is a valuable treatment option for the patients with statin intolerance. Pemafibrate, the first selective peroxisome proliferator-activated receptor alpha modulator, showed a favorable benefit-risk balance in phase 2 trial, but the large clinical phase 3 trial (PROMINENT) was recently stopped for futility based on a late interim analysis. High dose icosapent ethyl, a modified eicosapentaenoic acid preparation, shows cardiovascular benefits. Evinacumab, an angiopoietin-like 3 (ANGPTL3) monoclonal antibody, reduces plasma LDL-C levels in patients with refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, and lipoprotein(a) have significantly attenuated the levels of their target molecules with beneficial effects on associated dyslipidemias. Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid clinical evidence is necessary. In this review, we discuss the mode of action and clinical outcomes of these novel lipid-lowering agents beyond statins.

Citations

Citations to this article as recorded by

The mechanism of perilla oil in regulating lipid metabolism
Jiawei Xia, Yi Wang, Xin Li, Li Liu, Pin Zhang, Wendong Dai, Peng Luo, Guoze Wang, Yanhong Li
Food Chemistry.2025; 476: 143318. CrossRef
The effect of vitamin E supplementation on serum low-density lipoprotein oxidization: A systematic review and meta-analysis of clinical trials
Sepide Amini, Fatemeh Navab, Mohammad Hossein Rouhani, Tannaz Jamialahmadi, Mohammad Bagherniya, Prashant Kesharwani, Amirhossein Sahebkar
European Journal of Pharmacology.2025; 997: 177491. CrossRef
Acromegaly and the risk of cancer: a nationwide population-based cohort study in Korea
Yeo Song Kim, Jae-Seung Yun, Hyunho Kim, Sin Soo Jeun, Bongseong Kim, Sea-Won Lee, Jung Eun Lee, Kyuho Kim, Seung-Hyun Ko, Yu-Bae Ahn, Kyungdo Han, Seung Ho Yang
European Journal of Endocrinology.2025; 192(3): 220. CrossRef
Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
Katia Azarfar, Boris Decourt, Brandon Sanchez Camacho, John Joshua Lawrence, Tania R. Omondi, Marwan N. Sabbagh
Expert Review of Neurotherapeutics.2025; 25(5): 521. CrossRef
Recent Advances in the Management of Dyslipidemia: A Systematic Review
Huang Jacky Xiao Feng, Yousaf Adil, Moon Julie, Ahmed Ramiz, Uppal Krishma, Sudhakar Pemminati
Cureus.2025;[Epub] CrossRef
Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins
Gala Araujo, Leidy Marian Valencia, Agata Martin-Ozimek, Yosdel Soto, Spencer D. Proctor
Frontiers in Immunology.2025;[Epub] CrossRef
The role of adherence in patients with chronic diseases
Michel Burnier
European Journal of Internal Medicine.2024; 119: 1. CrossRef
Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
Frontiers in Endocrinology.2024;[Epub] CrossRef
Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Monika I. Konaklieva, Balbina J. Plotkin
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
Journal of Cardiovascular Development and Disease.2024; 11(3): 72. CrossRef
Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
Heliyon.2024; 10(7): e28837. CrossRef
Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660. CrossRef
Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction
Ziyi Sun, Zhangjun Yun, Jianguo Lin, Xiaoning Sun, Qingqing Wang, Jinlong Duan, Cheng Li, Xiaoxiao Zhang, Siyu Xu, Zeqi Wang, Xingjiang Xiong, Kuiwu Yao
Journal of Translational Medicine.2024;[Epub] CrossRef
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Eeshal Fatima, Faryal Altaf, Timothy J. Vittorio
Annals of Medicine & Surgery.2024; 86(5): 2818. CrossRef
Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
Galenika Medical Journal.2024; 3(9): 31. CrossRef
Lipid Variability Induces Endothelial Dysfunction by Increasing Inflammation and Oxidative Stress
Marie Rhee, Joonyub Lee, Eun Young Lee, Kun-Ho Yoon, Seung-Hwan Lee
Endocrinology and Metabolism.2024; 39(3): 511. CrossRef
Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study
Sarah Baig, Shahrauz Mughal, Yousuf Murad, Mandeep Virdee, Zahraa Jalal
Pharmacy.2024; 12(4): 104. CrossRef
Need of education and training of healthcare professionals on the PCSK9 inhibitors in cardiovascular disease
Jan Schjøtt, Kristine Heitmann
European Journal of Cardiovascular Nursing.2024; 23(8): e191. CrossRef
CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
Xize Wu, Changbin Yuan, Jiaxiang Pan, Yi Zhou, Xue Pan, Jian Kang, Lihong Ren, Lihong Gong, Yue Li
Scientific Reports.2024;[Epub] CrossRef
Lessons from PROMINENT and prospects for pemafibrate
Jean-Charles Fruchart, Jamila Fruchart-Najib, Shizuya Yamashita, Peter Libby, Koutaro Yokote, Tatsuhiko Kodama, Yohei Tomita, Paul M. Ridker, Michel P. Hermans, Alberto Zambon
Cardiovascular Diabetology.2024;[Epub] CrossRef
A novel lncRNA GM47544 modulates triglyceride metabolism by inducing ubiquitination-dependent protein degradation of APOC3
Qianqian Xiao, Luyun Wang, Jing Wang, Man Wang, Dao Wen Wang, Hu Ding
Molecular Metabolism.2024; 88: 102011. CrossRef
Advances in pharmacotherapy of dyslipidemia
Harshitha Chinta
National Journal of Pharmacology and Therapeutics.2024; 2(2): 68. CrossRef
ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
Jingfei Chen, Qin Luo, Yanfeng Yi, Jiangang Wang, Pengfei Chen, Fei Luo, Zhenfei Fang
Lipids in Health and Disease.2024;[Epub] CrossRef
Assessing the effects of HMGCR, LPL, and PCSK9 inhibition on sleep apnea: Mendelian randomization analysis of drug targets
Wei Tan, Xiujuan Deng, Xiaoning Tan, Guangbo Tan
Medicine.2024; 103(43): e40194. CrossRef
Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study
Lei Zhong, Bo Xie, Hai-Li Wang, Xiao-Wei Ji
Scientific Reports.2024;[Epub] CrossRef
A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction
Jing-Hui Wang, Guan-Rui Pan, Long Jiang
Frontiers in Immunology.2024;[Epub] CrossRef
Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
Beibei Hou, Linhui Qin, Linfeng Huang
Biochemical and Biophysical Research Communications.2023; 644: 85. CrossRef
Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
C. M. Schooling, J. V. Zhao
Current Cardiology Reports.2023; 25(2): 67. CrossRef
Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
Food Science & Nutrition.2023; 11(6): 2620. CrossRef
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206. CrossRef
Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
Journal of the American Heart Association.2023;[Epub] CrossRef
The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
Frontiers in Physiology.2023;[Epub] CrossRef
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Alejandro Gugliucci
Journal of Clinical Medicine.2023; 12(13): 4399. CrossRef
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206. CrossRef
Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
Pharmacy.2023; 11(4): 130. CrossRef
Advances in Treatment of Dyslipidemia
Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
International Journal of Molecular Sciences.2023; 24(17): 13288. CrossRef
Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
Biomedicines.2023; 11(10): 2696. CrossRef
Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
Scientific Reports.2023;[Epub] CrossRef
Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
Current Oncology.2023; 30(9): 8386. CrossRef
Riesgo residual. Conclusiones
Ángel Cequier, José Luis Zamorano
Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef
Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
Frontiers in Endocrinology.2023;[Epub] CrossRef
Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
Journal of Health, Population and Nutrition.2023;[Epub] CrossRef
Bempedoic acid: new evidence and recommendations on use
Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
Current Opinion in Lipidology.2023;[Epub] CrossRef
Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
Biology.2022; 11(9): 1308. CrossRef
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinology and Metabolism.2022; 37(4): 575. CrossRef

Original Article

Basic Research
Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice: Songling Jiang, Md Jamal Uddin, Xiaoying Yu, Lingjuan Piao, Debra Dorotea, Goo Taeg Oh, Hunjoo Ha; Diabetes Metab J. 2022;46(6):829-842. Published online June 24, 2022; DOI: https://doi.org/10.4093/dmj.2021.0274

8,080 View
338 Download
12 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Non-alcoholic fatty liver disease (NAFLD) has been increasing in association with the epidemic of obesity and diabetes. Peroxisomes are single membrane-enclosed organelles that play a role in the metabolism of lipid and reactive oxygen species. The present study examined the role of peroxisomes in high-fat diet (HFD)-induced NAFLD using fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist.
Methods
Eight-week-old male C57BL/6J mice were fed either a normal diet or HFD for 12 weeks, and fenofibrate (50 mg/kg/day) was orally administered along with the initiation of HFD.
Results
HFD-induced liver injury as measured by increased alanine aminotransferase, inflammation, oxidative stress, and lipid accumulation was effectively prevented by fenofibrate. Fenofibrate significantly increased the expression of peroxisomal genes and proteins involved in peroxisomal biogenesis and function. HFD-induced attenuation of peroxisomal fatty acid oxidation was also significantly restored by fenofibrate, demonstrating the functional significance of peroxisomal fatty acid oxidation. In Ppara deficient mice, fenofibrate failed to maintain peroxisomal biogenesis and function in HFD-induced liver injury.
Conclusion
The present data highlight the importance of PPARα-mediated peroxisomal fitness in the protective effect of fenofibrate against NAFLD.

Citations

Citations to this article as recorded by

PEX11B palmitoylation couples peroxisomal dysfunction with Schwann cells fail in diabetic neuropathy
Yu Mei Yang, Hang Bin Ma, Yue Xiong, Qian Wu, Xiu Kui Gao
Journal of Biomedical Science.2025;[Epub] CrossRef
Fenofibrate promotes erucic acid (EA) metabolism by peroxisome enzyme EHHADH activation alleviating HFD-induced steatotic liver disease
Ming Jin, Rongmi Zhang, Wenwen Xin, Li Sun, Xue Fan, Qian Lu, Luyong Zhang, Zhenzhou Jiang, Qinwei Yu
Molecular Pharmacology.2025; : 100047. CrossRef
Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Young-Su Yi
Journal of Ginseng Research.2024; 48(2): 122. CrossRef
Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function
Xuemei Wang, Jieying Wang, Cao Ying, Yuan Xing, Xuan Su, Ke Men
BMC Pharmacology and Toxicology.2024;[Epub] CrossRef
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
Diabetes & Metabolism Journal.2024; 48(2): 184. CrossRef
Lactobacillus plantarum NCHBL-004 modulates high-fat diet–induced weight gain and enhances GLP-1 production for blood glucose regulation
Ah-Ra Jang, Do-Hyeon Jung, Tae-Sung Lee, Jeon-Kyung Kim, Yu-Bin Lee, Jae-Young Lee, So-Yeon Kim, Yung-Choon Yoo, Jae-Hee Ahn, Eun-Hye Hong, Chae-Won Kim, Su Min Kim, Hye Hyun Yoo, Joo Young Huh, Hyun-Jeong Ko, Jong-Hwan Park
Nutrition.2024; 128: 112565. CrossRef
Peroxisome Proliferator Activator α Agonist Clofibrate Induces Pexophagy in Coconut Oil-Based High-Fat Diet-Fed Rats
Kanami Ohshima, Emika Hara, Mio Takimoto, Yidan Bai, Mai Hirata, Wen Zeng, Suzuka Uomoto, Mai Todoroki, Mio Kobayashi, Takuma Kozono, Tetsuhito Kigata, Makoto Shibutani, Toshinori Yoshida
Biology.2024; 13(12): 1027. CrossRef
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Manuela Vitulo, Elisa Gnodi, Giulia Rosini, Raffaella Meneveri, Roberto Giovannoni, Donatella Barisani
International Journal of Molecular Sciences.2023; 24(16): 12748. CrossRef
PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
Tiantian Liu, Xinlu Chen, Ziqi Wei, Xue Han, Yujia Liu, Zhengliang Ma, Tianjiao Xia, Xiaoping Gu
Translational Neuroscience.2023;[Epub] CrossRef
Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo
Frontiers in Nutrition.2022;[Epub] CrossRef

Review

Drug/Regimen
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction: Nam Hoon Kim, Sin Gon Kim; Diabetes Metab J. 2020;44(2):213-221. Published online April 23, 2020; DOI: https://doi.org/10.4093/dmj.2020.0001

12,193 View
419 Download
60 Web of Science
63 Crossref

Abstract PDF PubReader

Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.

Citations

Citations to this article as recorded by

Apolipoprotein B-containing lipoproteins in atherogenesis
Jan Borén, Chris J. Packard, Christoph J. Binder
Nature Reviews Cardiology.2025; 22(6): 399. CrossRef
Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials
Luis E. Simental-Mendia, Mario Simental-Mendía, Claudia I. Gamboa-Gomez, Tannaz Jamialahmadi, Amirhossein Sahebkar
Current Pharmaceutical Design.2025; 31(15): 1205. CrossRef
Fatty acid binding proteins-mediated mitochondrial dysfunction in the development of age-related diseases: A review
Xingxing Ren, Chaoyuan Jin, Qilin Li, Congyi Fu, Yu Fang, Zihang Xu, Zi Liang, Tianshi Wang
International Journal of Biological Macromolecules.2025; 309: 142913. CrossRef
An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease
Anqi Feng, Ruili Yin, Rong Xu, Baoyu Zhang, Longyan Yang
Frontiers in Pharmacology.2025;[Epub] CrossRef
Novel carboxamide derivatives increase lipoprotein lipase gene expression in endothelial and adipose tissues of triton WR- 1339 induced hyperlipidemic rats
Suhair Hikmat, Aya Hasan, Lama Hamadneh, Mohammad Alwahsh, Sameer Al-Kouz, Yusuf Al-Hiari, Basmah Al-Jammal, Tariq Al-Qirim, Buthaina Hussein
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
The approach to triglyceride levels in patients with coronary heart disease
Ilay Shani, Avishay Elis
European Journal of Internal Medicine.2025;[Epub] CrossRef
Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial
Eman M. Nada, Nashwa M. El-Gharbawy, Haidy Abbas, Rehab H. Werida
BMC Pharmacology and Toxicology.2025;[Epub] CrossRef
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118. CrossRef
Role of PPARα in inflammatory response of C2C12 myotubes
Yuki Shimizu, Keiko Hamada, Tingting Guo, Chie Hasegawa, Yusuke Kuga, Katsushi Takeda, Takashi Yagi, Hiroyuki Koyama, Hiroshi Takagi, Daisuke Aotani, Hiromi Kataoka, Tomohiro Tanaka
Biochemical and Biophysical Research Communications.2024; 694: 149413. CrossRef
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
John J. P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson
Current Atherosclerosis Reports.2024; 26(2): 35. CrossRef
Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases
Virginia Actis Dato, Stephan Lange, Yoshitake Cho
International Journal of Molecular Sciences.2024; 25(2): 1211. CrossRef
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Angelos Evangelopoulos, Fotis Panagopoulos, Theodora Stratigou, Eleni Geladari, Irene Karampela, Maria Dalamaga
Metabolites.2024; 14(2): 123. CrossRef
Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population
N. Ponce-Ruíz, J. F. Herrera-Moreno, A. E. Rojas-García, B. S. Barrón-Vivanco, C. A. González-Arias, Y. Y. Bernal-Hernández, L. Ortega-Cervantes, J. Ponce-Gallegos, J. A. Hernández-Nolasco, I. M. Medina-Díaz
Heart and Vessels.2024; 39(6): 563. CrossRef
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
Diabetes & Metabolism Journal.2024; 48(2): 184. CrossRef
Coenzyme Q10 in atherosclerosis
Minjun Liao, Xueke He, Yangyang Zhou, Weiqiang Peng, Xiao-Mei Zhao, Miao Jiang
European Journal of Pharmacology.2024; 970: 176481. CrossRef
Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
Maria Paravati, Anna Procopio, Maja Milanović, Giuseppe Scarlata, Nataša Milošević, Maja Ružić, Nataša Milić, Ludovico Abenavoli
Nutrients.2024; 16(8): 1226. CrossRef
Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Katarina Lalić, Nataša Rajković, Ljiljana Popović, Sandra Singh-Lukač, Iva Rasulić, Ana Petakov, Milica Krstić, Marija Mitrović
Galenika Medical Journal.2024; 3(9): 31. CrossRef
Research trends in lipid-lowering therapies for coronary heart disease combined with hyperlipidemia: a bibliometric study and visual analysis
Quankai Cheng, Jingjing Sun, Haicheng Zhong, Ziming Wang, Chang Liu, Sheng Zhou, Jie Deng
Frontiers in Pharmacology.2024;[Epub] CrossRef
Expression of FAM159B in Humans, Rats, and Mice: A Cross-species Examination
Anna-Sophia Liselott Beyer, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp
Journal of Histochemistry & Cytochemistry.2024; 72(7): 467. CrossRef
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga
Metabolites.2024; 14(7): 388. CrossRef
Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
Cardiovascular Diabetology.2024;[Epub] CrossRef
The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: A comprehensive review
Leisheng Wang, Shiwei Xu, Mengzhen Zhou, Hao Hu, Jinyou Li
International Journal of Biological Macromolecules.2024; 278: 134835. CrossRef
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factor
Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong J
Endocrinology and Metabolism.2024; 39(5): 722. CrossRef
Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
Endocrine Practice.2024; 30(11): 1103. CrossRef
Effects of Fatty Acid Metabolism on Heart Failure
日娜萨
Advances in Clinical Medicine.2024; 14(09): 787. CrossRef
Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis
Yiran Chen, Kunyu Zheng, Gahu Da, Xu Wang, Yi Wei, Guochun Wang, Fengchun Zhang, Li Wang
Expert Opinion on Pharmacotherapy.2024; 25(13): 1825. CrossRef
Integrated review of cardiometabolic biomarkers and dietary nutrients
Ravindra Verma, Prakash S Bisen, Mònica Bulló
Journal of Food Bioactives.2024; : 44. CrossRef
Cardiovascular Diseases and Metabolic Medications in the Lebanese Population: A Post Hoc Analysis from a Nationwide Cross-Sectional Study
Rony M. Zeenny, Rachel Abdo, Chadia Haddad, Aline Hajj, Rouba Karen Zeidan, Pascale Salameh, Jean Ferrieres
Pharmacy.2024; 12(6): 171. CrossRef
From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Disease
Wenchao Xu, Yuting Zhu, Siyuan Wang, Jihong Liu, Hao Li
Antioxidants.2024; 13(12): 1540. CrossRef
Exploring the mechanism of fibrates regulating HIF-1A in the treatment of ischemic stroke based on network pharmacology and molecular docking
Fengjiao Yang, Zixuan Yang, Ya Yan, Yun Gu, Pengyu Wang, Min Wang, Jianjie Chen, Xiaoshan Du, Guangming Wang
BMC Research Notes.2024;[Epub] CrossRef
Present and Future of Dyslipidaemia Treatment—A Review
Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Radman, Ivan Pećin, Željko Reiner
Journal of Clinical Medicine.2023; 12(18): 5839. CrossRef
VLDL receptor gene therapy for reducing atherogenic lipoproteins
Ronald M. Krauss, Jonathan T. Lu, Joseph J. Higgins, Cathryn M. Clary, Ray Tabibiazar
Molecular Metabolism.2023; 69: 101685. CrossRef
The emerging role of PPAR-alpha in breast cancer
Zhiwen Qian, Lingyan Chen, Jiayu Liu, Ying Jiang, Yan Zhang
Biomedicine & Pharmacotherapy.2023; 161: 114420. CrossRef
Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
Yujie Pu, Chak Kwong Cheng, Hongsong Zhang, Jiang‐Yun Luo, Li Wang, Brian Tomlinson, Yu Huang
Medicinal Research Reviews.2023; 43(6): 2086. CrossRef
Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism
DuoYao Cao, Zakir Khan, Xiaomo Li, Suguru Saito, Ellen A Bernstein, Aaron R Victor, Faizan Ahmed, Aoi O Hoshi, Luciana C Veiras, Tomohiro Shibata, Mingtian Che, Lei Cai, Michifumi Yamashita, Ryan E Temel, Jorge F Giani, Daniel J Luthringer, Ajit S Divakar
Cardiovascular Research.2023; 119(9): 1825. CrossRef
Rapid flow synthesis of fenofibrate via scalable flash chemistry with in-line Li recovery
Sanket A. Kawale, Dong-Chang Kang, Gwang-Noh Ahn, Amirreza Mottafegh, Ji-Ho Kang, Gi-Su Na, Dong-Pyo Kim
Chemical Engineering Journal.2023; 477: 147033. CrossRef
Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
Marat V. Ezhov, Gregory P. Arutyunov
Diseases.2023; 11(4): 140. CrossRef
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Giulio Preta
Cells.2023; 12(20): 2466. CrossRef
Exploring the hypolipidemic effects of bergenin from Saxifraga melanocentra Franch: mechanistic insights and potential for hyperlipidemia treatment
Li Zhang, Yingying Tong, Yan Fang, Jinjin Pei, Qilan Wang, Gang Li
Lipids in Health and Disease.2023;[Epub] CrossRef
Obesity and Dyslipidemia
Barbora Nussbaumerova, Hana Rosolova
Current Atherosclerosis Reports.2023; 25(12): 947. CrossRef
Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
Journal of Health, Population and Nutrition.2023;[Epub] CrossRef
Hypertriglyceridemia in Apoa5–/– mice results from reduced amounts of lipoprotein lipase in the capillary lumen
Ye Yang, Anne P. Beigneux, Wenxin Song, Le Phuong Nguyen, Hyesoo Jung, Yiping Tu, Thomas A. Weston, Caitlyn M. Tran, Katherine Xie, Rachel G. Yu, Anh P. Tran, Kazuya Miyashita, Katsuyuki Nakajima, Masami Murakami, Yan Q. Chen, Eugene Y. Zhen, Joonyoung R.
Journal of Clinical Investigation.2023;[Epub] CrossRef
Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update
Dipali Kale, Amol Fatangare, Prasad Phapale, Albert Sickmann
Cells.2023; 12(24): 2796. CrossRef
Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia
Gary F Lewis, Robert A Hegele
The Lancet Diabetes & Endocrinology.2022; 10(2): 142. CrossRef
Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel
Biomedicines.2022; 10(1): 193. CrossRef
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
World Journal of Hepatology.2022; 14(1): 119. CrossRef
Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
Ana Clara Aprotosoaie, Alexandru-Dan Costache, Irina-Iuliana Costache
Pharmaceutics.2022; 14(4): 722. CrossRef
The Overlooked Transformation Mechanisms of VLCFAs: Peroxisomal β-Oxidation
Qinyue Lu, Weicheng Zong, Mingyixing Zhang, Zhi Chen, Zhangping Yang
Agriculture.2022; 12(7): 947. CrossRef
Current Trends of Big Data Research Using the Korean National Health Information Database
Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
Diabetes & Metabolism Journal.2022; 46(4): 552. CrossRef
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
Diabetes & Metabolism Journal.2022; 46(4): 517. CrossRef
Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure
Agata Jedrzejewska, Alicja Braczko, Ada Kawecka, Marcin Hellmann, Piotr Siondalski, Ewa Slominska, Barbara Kutryb-Zajac, Magdi H. Yacoub, Ryszard T. Smolenski
International Journal of Molecular Sciences.2022; 23(17): 9886. CrossRef
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Joon Ho Moon, Kyuho Kim, Sung Hee Choi
Endocrinology and Metabolism.2022; 37(4): 575. CrossRef
Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
Metabolism.2022; 137: 155327. CrossRef
Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
Veronika Vyletelová, Mária Nováková, Ľudmila Pašková
Pharmaceuticals.2022; 15(10): 1278. CrossRef
Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
Cristina Gavina, Daniel Seabra Carvalho, Marisa Pardal, Marta Afonso-Silva, Diana Grangeia, Ricardo Jorge Dinis-Oliveira, Francisco Araújo, Tiago Taveira-Gomes
Journal of Clinical Medicine.2022; 11(22): 6825. CrossRef
New and Emerging lipid-lowering Therapy
James M Backes, Daniel E Hilleman
Future Cardiology.2021; 17(8): 1407. CrossRef
Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
Styliani Fragki, Hubert Dirven, Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gützkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Z
Critical Reviews in Toxicology.2021; 51(2): 141. CrossRef
A network pharmacology analysis on drug‐like compounds from Ganoderma lucidum for alleviation of atherosclerosis
Ki Kwang Oh, Md. Adnan, Dong Ha Cho
Journal of Food Biochemistry.2021;[Epub] CrossRef
Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
Myung Soo Park, Jong-Chan Youn, Eung Ju Kim, Ki Hoon Han, Sang Hak Lee, Sung Hea Kim, Byung Jin Kim, Sung Uk Kwon, Kyu-Hyung Ryu
Clinical Therapeutics.2021; 43(10): 1735. CrossRef
Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
Louis Jacob, Roger-Axel Greiner, Mark Luedde, Karel Kostev
Journal of Cardiovascular Pharmacology.2021; 78(6): 885. CrossRef
Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
Leili Rahimi, Mojtaba Malek, Faramarz Ismail-Beigi, Mohammad E. Khamseh
Advances in Therapy.2020; 37(8): 3450. CrossRef
Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats
Corbin A. Shields, Bibek Poudel, Kasi C. McPherson, Andrea K. Brown, Ubong S. Ekperikpe, Evan Browning, Lamari Sutton, Denise C. Cornelius, Jan M. Williams
Frontiers in Physiology.2020;[Epub] CrossRef
Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
Amelia Charlton, Jessica Garzarella, Karin A. M. Jandeleit-Dahm, Jay C. Jha
Biology.2020; 10(1): 18. CrossRef

Original Article

Adipose Gene Expression Profiles Related to Metabolic Syndrome Using Microarray Analyses in Two Different Models: Hye Jin Yoo, Hwan-Jin Hwang, Tae Woo Jung, Ja Young Ryu, Ho Cheol Hong, Hae Yoon Choi, Sei Hyun Baik, Kyung Mook Choi; Diabetes Metab J. 2014;38(5):356-365. Published online October 17, 2014; DOI: https://doi.org/10.4093/dmj.2014.38.5.356

5,526 View
49 Download
7 Web of Science
7 Crossref

Abstract PDF PubReader

Background

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist has a wide-ranging influence on multiple components of metabolic syndrome. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is a useful animal model of metabolic syndrome. To determine genes related to metabolic syndrome, we examined overlapping genes that are simultaneously decreased by PPAR-γ agonists and increased in OLETF rats using microarrays in two different models.

Methods

In the first microarray analysis, PPAR-γ agonist-treated db/db mice were compared to standard diet-fed db/db mice. In the second microarray analysis, OLETF rats were compared to Long-Evans Tokushima Otsuka (LETO) rats (control of OLETF rats).

Results

Among the overlapping genes, in the present study, we validated that lipocalin-2 expression was significantly decreased in the visceral adipose tissue of PPAR-γ agonist-treated db/db mice compared to standard diet-fed db/db mice and increased in OLETF rats compared to LETO rats using real time reverse transcription polymerase chain reaction. Furthermore, we showed for the first time that lipocalin-2 expression was significantly increased in the visceral adipose tissues of obese humans compared with nonobese humans. In addition, the expression level of lipocalin-2 in human visceral adipose tissue had a significant positive correlation with body mass index, serum interleukin-6, adipocyte fatty acid binding protein levels, and white blood cell count.

Conclusion

Lipocalin-2 was confirmed to be a significant adipokine affected by PPAR-γ agonist and obesity in the present study. Also, for the first time in human visceral adipose tissue, it was determined that the expression of lipocalin-2 from obese humans was significantly increased and correlated with circulating inflammatory markers.

Citations

Citations to this article as recorded by

Lipocalin‐2—The myth of its expression and function
Dahui Li, Wai Yan Sun, Bowen Fu, Aimin Xu, Yu Wang
Basic & Clinical Pharmacology & Toxicology.2020; 127(2): 142. CrossRef
Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes
Ioanna Mosialou, Steven Shikhel, Na Luo, Peristera Ioanna Petropoulou, Konstantinos Panitsas, Brygida Bisikirska, Nyanza J. Rothman, Roxane Tenta, Bertrand Cariou, Matthieu Wargny, Elisabeth Sornay-Rendu, Thomas Nickolas, Mishaela Rubin, Cyrille B. Confav
Journal of Experimental Medicine.2020;[Epub] CrossRef
Metabolism and adult neurogenesis: Towards an understanding of the role of lipocalin-2 and iron-related oxidative stress
Ana Catarina Ferreira, Nuno Sousa, João M. Bessa, João Carlos Sousa, Fernanda Marques
Neuroscience & Biobehavioral Reviews.2018; 95: 73. CrossRef
LH-21, A Peripheral Cannabinoid Receptor 1 Antagonist, Exerts Favorable Metabolic Modulation Including Antihypertensive Effect in KKAy Mice by Regulating Inflammatory Cytokines and Adipokines on Adipose Tissue
Ziqi Dong, Hui Gong, Yadan Chen, Hong Wu, Jun Wu, Yinghong Deng, Xinmao Song
Frontiers in Endocrinology.2018;[Epub] CrossRef
Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue
Prasad G. Kamble, Maria J. Pereira, Cherno O. Sidibeh, Sam Amini, Magnus Sundbom, Joey Lau Börjesson, Jan W. Eriksson
Molecular and Cellular Endocrinology.2016; 427: 124. CrossRef
Serum lipocalin-2 levels are positively associated with not only total body fat but also visceral fat area in Chinese men
Yuqi Luo, Xiaojing Ma, Xiaoping Pan, Yiting Xu, Qin Xiong, Yunfeng Xiao, Yuqian Bao, Weiping Jia
Medicine.2016; 95(30): e4039. CrossRef
From the periphery to the brain: Lipocalin-2, a friend or foe?
Ana C. Ferreira, Sandro Dá Mesquita, João C. Sousa, Margarida Correia-Neves, Nuno Sousa, Joana A. Palha, Fernanda Marques
Progress in Neurobiology.2015; 131: 120. CrossRef

Review

Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity: Cesar Corzo, Patrick R. Griffin; Diabetes Metab J. 2013;37(6):395-403. Published online December 12, 2013; DOI: https://doi.org/10.4093/dmj.2013.37.6.395

6,142 View
59 Download
34 Crossref

Abstract PDF PubReader

Adipose tissue, which was once viewed as a simple organ for storage of triglycerides, is now considered an important endocrine organ. Abnormal adipose tissue mass is associated with defects in endocrine and metabolic functions which are the underlying causes of the metabolic syndrome. Many adipokines, hormones secreted by adipose tissue, regulate cells from the immune system. Interestingly, most of these adipokines are proinflammatory mediators, which increase dramatically in the obese state and are believed to be involved in the pathogenesis of insulin resistance. Drugs that target peroxisome proliferator-activated receptor-γ have been shown to possess anti-inflammatory effects in animal models of diabetes. These findings, and the link between inflammation and the metabolic syndrome, will be reviewed here.

Citations

Citations to this article as recorded by

Lysine 222 in PPAR γ1 functions as the key site of MuRF2-mediated ubiquitination modification
Yucheng Fan, Fangjing Xu, Rui Wang, Jun He
Scientific Reports.2023;[Epub] CrossRef
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Terri Jerkins, Janet B. McGill, David S. H. Bell
Diabetes, Obesity and Metabolism.2023; 25(S3): 3. CrossRef
The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics
Gargi Dixit, Arati Prabhu
Experimental and Molecular Pathology.2022; 124: 104723. CrossRef
The Effect of PPARγ rs1801282 Variant on Mortality Risk Among Asians With Chronic Kidney Disease: A Cohort Study and Meta-Analysis
Wei-Teing Chen, Chih-Chien Chiu, Dung-Jang Tsai, Pi-Shao Ko, Meng-Chang Lee, Hsiao-Ting Lin, Ying-Kai Chen, Wen Su, Yuh-Feng Lin, Sui-Lung Su
Frontiers in Genetics.2022;[Epub] CrossRef
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh
International Journal of Molecular Sciences.2021; 22(9): 4495. CrossRef
Associations between obesity-related gene expression in maternal and cord blood and newborn adiposity: findings from the Araraquara Cohort study
P. Nakandakare, C. F. Nicoletti, N. Y. Noronha, C. B. Nonino, P. P. Argentato, N. N. Dejani, L. A. Luzia, M. M. Rogero, P. H. C. Rondó
International Journal of Obesity.2021; 45(9): 1958. CrossRef
PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study—A Key for Reaching Null Association
Hsiang-Cheng Chen, Wei-Teing Chen, Tzu-Ling Sung, Dung-Jang Tsai, Chin Lin, Hao Su, Yuh-Feng Lin, Hung-Yi Chiu, Sui-Lung Su
Genes.2020; 11(6): 705. CrossRef
Induction of peroxisome proliferator activated receptor γ (PPARγ) mediated gene expression and inhibition of induced nitric oxide production by Maerua subcordata (Gilg) DeWolf
Mebrahtom Gebrelibanos Hiben, Laura de Haan, Bert Spenkelink, Sebastiaan Wesseling, Jacques Vervoort, Ivonne M. C. M. Rietjens
BMC Complementary Medicine and Therapies.2020;[Epub] CrossRef
UPR modulation of host immunity by Pseudomonas aeruginosa in cystic fibrosis
Brahmchetna Bedi, Kuo-Chuan. Lin, Nicholas M. Maurice, Zhihong Yuan, Kaiser Bijli, Michael Koval, C. Michael Hart, Joanna B. Goldberg, Arlene Stecenko, Ruxana T. Sadikot
Clinical Science.2020; 134(14): 1911. CrossRef
Sepsis Immunometabolism: From Defining Sepsis to Understanding How Energy Production Affects Immune Response
Ioannis Koutroulis, Rachael Batabyal, Brittany McNamara, Matthew Ledda, Claire Hoptay, Robert J. Freishtat
Critical Care Explorations.2019; 1(11): e0061. CrossRef
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
Eugene Han, Eugene Shin, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Frontiers in Endocrinology.2018;[Epub] CrossRef
Role of oral hypoglycemic drugs on inflammatory condition associated with type 2 diabetes mellitus
Shamim Shaikh Mohiuddin
Journal of Diabetes, Metabolic Disorders & Control.2018; 5(2): 78. CrossRef
Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
Bong-Hoi Choi, Zhen Jin, Chin-ok Yi, Juhong Oh, Eun Ae Jeong, Jong Youl Lee, Kyung-ah Park, Kyung Eun Kim, Jung Eun Lee, Hyun-Jin Kim, Jong Ryeal Hahm, Gu Seob Roh, Jonathan M Peterson
PLOS ONE.2018; 13(7): e0200336. CrossRef
Cucurbita ficifolia (Cucurbitaceae) modulates inflammatory cytokines and IFN-γ in obese mice
Á. Fortis-Barrera, R. García-Macedo, J.C. Almanza-Perez, G. Blancas-Flores, A. Zamilpa-Alvarez, J.L. Flores-Sáenz, M. Cruz, R. Román-Ramos, F.J. Alarcón-Aguilar
Canadian Journal of Physiology and Pharmacology.2017; 95(2): 170. CrossRef
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
Yong-ho Lee, Jae Hyeon Kim, So Ra Kim, Heung Yong Jin, Eun-Jung Rhee, Young Min Cho, Byung-Wan Lee
Journal of Korean Medical Science.2017; 32(1): 60. CrossRef
Peroxisome proliferator‐activated receptor‐γ agonists attenuate biofilm formation by Pseudomonas aeruginosa
Brahmchetna Bedi, Nicholas M. Maurice, Vincent T. Ciavatta, K. Sabrina Lynn, Zhihong Yuan, Samuel A. Molina, Myungsoo Joo, William R. Tyor, Joanna B. Goldberg, Michael Koval, C. Michael Hart, Ruxana T. Sadikot
The FASEB Journal.2017; 31(8): 3608. CrossRef
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren, Jan Westerink
Cardiovascular Diabetology.2017;[Epub] CrossRef
Gestational diabetes mellitus was related to ambient air pollutant nitric oxide during early gestation
Shih-Chun Pan, Ching-Chun Huang, Shio-Jean Lin, Bing-Yu Chen, Chang-Chuan Chan, Yue-Liang Leon Guo
Environmental Research.2017; 158: 318. CrossRef
The Multifaceted Haptoglobin in the Context of Adipose Tissue and Metabolism
Margherita Maffei, Ilaria Barone, Gaia Scabia, Ferruccio Santini
Endocrine Reviews.2016; 37(4): 403. CrossRef
Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor Gamma
Brahmchetna Bedi, Zhihong Yuan, Myungsoo Joo, Susu M. Zughaier, Joanna B. Goldberg, Jack L. Arbiser, C. Michael Hart, Ruxana T. Sadikot, B. A. McCormick
Infection and Immunity.2016; 84(7): 1975. CrossRef
F-box only protein 9 is an E3 ubiquitin ligase of PPARγ
Kyeong Won Lee, Soo Heon Kwak, Young Do Koo, Yun-Kyung Cho, Hak Mo Lee, Hye Seung Jung, Young Min Cho, Young Joo Park, Sung Soo Chung, Kyong Soo Park
Experimental & Molecular Medicine.2016; 48(5): e234. CrossRef
The Resin fromProtium heptaphyllumPrevents High-Fat Diet-Induced Obesity in Mice: Scientific Evidence and Potential Mechanisms
Karine Maria Martins Bezerra Carvalho, José Delano Barreto Marinho Filho, Tiago Sousa de Melo, Ana Jérsia Araújo, Josiane da Silva Quetz, Maria do Perpétuo Socorro Saldanha da Cunha, Karina Moura de Melo, Armenio Andre de Carvalho Almeida da Silva, Adrian
Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1. CrossRef
Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension
S.‐M. Jin, C.‐Y. Park, Y. M. Cho, B. J. Ku, C. W. Ahn, B.‐S. Cha, K. W. Min, Y. A. Sung, S. H. Baik, K. W. Lee, K.‐H. Yoon, M.‐K. Lee, S. W. Park
Diabetes, Obesity and Metabolism.2015; 17(6): 599. CrossRef
Deconvolution of Complex 1D NMR Spectra Using Objective Model Selection
Travis S. Hughes, Henry D. Wilson, Ian Mitchelle S. de Vera, Douglas J. Kojetin, Paul C. Driscoll
PLOS ONE.2015; 10(8): e0134474. CrossRef
PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes
Flora Aparecida Milton, Aleksandra Cvoro, Angelica A. Amato, Douglas H. Sieglaff, Carly S. Filgueira, Anithachristy Sigamani Arumanayagam, Maria do Carmo Alves de Lima, Ivan Rocha Pitta, Francisco de Assis Rocha Neves, Paul Webb
Biochemical and Biophysical Research Communications.2015; 464(3): 718. CrossRef
Voluntary exercise prevents colonic inflammation in high-fat diet-induced obese mice by up-regulating PPAR-γ activity
Wei-Xin Liu, Ting Wang, Feng Zhou, Ying Wang, Jun-Wei Xing, Shen Zhang, Shou-Zhi Gu, Li-Xuan Sang, Cong Dai, Hai-Lan Wang
Biochemical and Biophysical Research Communications.2015; 459(3): 475. CrossRef
Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis
Soo Lim, Kuy-Sook Lee, Jie Eun Lee, Ho Seon Park, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Kyong Soo Park, Young Bum Kim, Hak Chul Jang
Atherosclerosis.2015; 243(1): 107. CrossRef
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
A.J. Scheen, N. Esser, N. Paquot
Diabetes & Metabolism.2015; 41(3): 183. CrossRef
Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein
Yanxiao Zhang, Jingcheng Yu, Chee Lee, Bin Xu, Maureen A. Sartor, Ronald J. Koenig
Oncotarget.2015; 6(38): 40418. CrossRef
Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage
Santiago Garcia-Vallvé, Laura Guasch, Sarah Tomas-Hernández, Josep Maria del Bas, Vincent Ollendorff, Lluís Arola, Gerard Pujadas, Miquel Mulero
Journal of Medicinal Chemistry.2015; 58(14): 5381. CrossRef
Pathway Analysis of Metabolic Syndrome Using a Genome-Wide Association Study of Korea Associated Resource (KARE) Cohorts
Unjin Shim, Han-Na Kim, Yeon-Ah Sung, Hyung-Lae Kim
Genomics & Informatics.2014; 12(4): 195. CrossRef
Pax-8–PPAR-γ fusion protein in thyroid carcinoma
Priyadarshini Raman, Ronald J. Koenig
Nature Reviews Endocrinology.2014; 10(10): 616. CrossRef
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis
Shinan Yin, Hua Bai, Danqing Jing
Diagnostic Pathology.2014;[Epub] CrossRef
Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation
Ajaykumar N. Sharma, Isabelle E. Bauer, Marsal Sanches, Juan F. Galvez, Giovana B. Zunta-Soares, Joao Quevedo, Flavio Kapczinski, Jair C. Soares
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2014; 54: 289. CrossRef

Original Article

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones: Kyeong Won Lee, Yun Hyi Ku, Min Kim, Byung Yong Ahn, Sung Soo Chung, Kyong Soo Park; Diabetes Metab J. 2011;35(4):340-347. Published online August 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.4.340

6,368 View
46 Download
21 Crossref

Abstract PDF PubReader

Background

Sulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ), one of the nuclear receptors. In this study, we investigated the effects of sulfonylurea on PPARγ transcriptional activity and on the glucose uptake via PPARγ.

Methods

Transcription reporter assays using Cos7 cells were performed to determine if specific sulfonylureas stimulate PPARγ transactivation. Glimepiride, gliquidone, and glipizide (1 to 500 µM) were used as treatment, and rosiglitazone at 1 and 10 µM was used as a control. The effects of sulfonylurea and rosiglitazone treatments on the transcriptional activity of endogenous PPARγ were observed. In addition, 3T3-L1 adipocytes were treated with rosiglitazone (10 µM), glimepiride (100 µM) or both to verify the effect of glimepiride on rosiglitazone-induced glucose uptake.

Results

Sulfonylureas, including glimepiride, gliquidone and glipizide, increased PPARγ transcriptional activity, gliquidone being the most potent PPARγ agonist. However, no additive effects were observed in the presence of rosiglitazone. When rosiglitazone was co-treated with glimepiride, PPARγ transcriptional activity and glucose uptake were reduced compared to those after treatment with rosiglitazone alone. This competitive effect of glimepiride was observed only at high concentrations that are not achieved with clinical doses.

Conclusion

Sulfonylureas like glimepiride, gliquidone and glipizide increased the transcriptional activity of PPARγ. Also, glimepiride was able to reduce the effect of rosiglitazone on PPARγ agonistic activity and glucose uptake. However, the competitive effect does not seem to occur at clinically feasible concentrations.

Citations

Citations to this article as recorded by

Sulfonylureas exert antidiabetic action on adipocytes by inhibition of PPARγ serine 273 phosphorylation
Bodo Haas, Moritz David Sebastian Hass, Alexander Voltz, Matthias Vogel, Julia Walther, Arijit Biswas, Daniela Hass, Alexander Pfeifer
Molecular Metabolism.2024; 85: 101956. CrossRef
Chitosan-Encapsulated Nano-selenium Targeting TCF7L2, PPARγ, and CAPN10 Genes in Diabetic Rats
Omayma A. R. Abozaid, Sawsan M. El-Sonbaty, Neama M. A. Hamam, Moustafa A. Farrag, Ahmad S. Kodous
Biological Trace Element Research.2023; 201(1): 306. CrossRef
Insights from insulin resistance pathways: Therapeutic approaches against Alzheimer associated diabetes mellitus
Ayesha Fauzi, Ewen Se Thoe, Tang Yin Quan, Adeline Chia Yoke Yin
Journal of Diabetes and its Complications.2023; 37(11): 108629. CrossRef
Novel Sulfonanilide Inhibitors of SHIP2 Enhance Glucose Uptake into Cultured Myotubes
Mika E. A. Berg, Jette-Britt Naams, Laura C. Hautala, Tuomas A. Tolvanen, Jari P. Ahonen, Sanna Lehtonen, Kristiina Wähälä
ACS Omega.2020; 5(3): 1430. CrossRef
Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents
Agnieszka Jankowska, Anna Wesołowska, Maciej Pawłowski, Grażyna Chłoń-Rzepa
Current Medicinal Chemistry.2020; 27(39): 6658. CrossRef
Moringa concanensis Nimmo extracts ameliorates hyperglycemia-mediated oxidative stress and upregulates PPARγ and GLUT4 gene expression in liver and pancreas of streptozotocin-nicotinamide induced diabetic rats
Brindha Banu Balakrishnan, Kalaivani Krishnasamy, Vijayakumar Mayakrishnan, Arokiyaraj Selvaraj
Biomedicine & Pharmacotherapy.2019; 112: 108688. CrossRef
PPARγ Agonistic Activity of Sulphonylureas
Debjani Banerjee, Harnovdeep Singh Bharaj, Moulinath Banerjee
Endocrine, Metabolic & Immune Disorders - Drug Targets.2019; 19(4): 467. CrossRef
Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene
Zhimin Huang, Juan Liu, Kaka Ng, Xuesi Wan, Lijuan Xu, Xiaoying He, Zhihong Liao, Yanbing Li
Journal of Diabetes Investigation.2018; 9(5): 1075. CrossRef
Arsenic, Cadmium, and Lead Like Troglitazone Trigger PPARγ-Dependent Poly (ADP-Ribose) Polymerase Expression and Subsequent Apoptosis in Rat Brain Astrocytes
Rajesh Kushwaha, Juhi Mishra, Sachin Tripathi, Puneet Khare, Sanghamitra Bandyopadhyay
Molecular Neurobiology.2018; 55(3): 2125. CrossRef
Docosahexaenoic acid up‐regulates both PI3K/AKT‐dependent FABP7–PPARγ interaction and MKP3 that enhance GFAP in developing rat brain astrocytes
Sachin Tripathi, Rajesh Kushwaha, Juhi Mishra, Manoj Kumar Gupta, Harish Kumar, Somali Sanyal, Dhirendra Singh, Sabyasachi Sanyal, Amogh Anant Sahasrabuddhe, Mohan Kamthan, Mohana Krishna Reddy Mudiam, Sanghamitra Bandyopadhyay
Journal of Neurochemistry.2017; 140(1): 96. CrossRef
Antiglycation and cell protective actions of metformin and glipizide in erythrocytes and monocytes
Krishna Adeshara, Rashmi Tupe
Molecular Biology Reports.2016; 43(3): 195. CrossRef
The therapeutic journey of pyridazinone
Wasim Akhtar, M. Shaquiquzzaman, Mymoona Akhter, Garima Verma, Mohemmed Faraz Khan, M. Mumtaz Alam
European Journal of Medicinal Chemistry.2016; 123: 256. CrossRef
Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect
Chetna Kharbanda, Mohammad Sarwar Alam, Hinna Hamid, Kalim Javed, Abhijeet Dhulap, Sameena Bano, Yakub Ali
Bioorganic & Medicinal Chemistry Letters.2015; 25(20): 4601. CrossRef
Method Development and Validation of Amlodipine, Gliquidone and Pioglitazone: Application in the Analysis of Human Serum
Agha Zeeshan Mirza, M. Saeed Arayne, Najma Sultana
Analytical Chemistry Letters.2014; 4(5-6): 302. CrossRef
Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats
Jian-Ting Ke, Mi Li, Shi-Qing Xu, Wen-Jian Zhang, Yong-Wei Jiang, Lan-yun Cheng, Li Chen, Jin-Ning Lou, Wei Wu
Journal of Endocrinology.2014; 220(2): 129. CrossRef
Extension of Drosophila lifespan by cinnamon through a sex-specific dependence on the insulin receptor substrate chico
Samuel E. Schriner, Steven Kuramada, Terry E. Lopez, Stephanie Truong, Andrew Pham, Mahtab Jafari
Experimental Gerontology.2014; 60: 220. CrossRef
Crif1 Deficiency Reduces Adipose OXPHOS Capacity and Triggers Inflammation and Insulin Resistance in Mice
Min Jeong Ryu, Soung Jung Kim, Yong Kyung Kim, Min Jeong Choi, Surendar Tadi, Min Hee Lee, Seong Eun Lee, Hyo Kyun Chung, Saet Byel Jung, Hyun-Jin Kim, Young Suk Jo, Koon Soon Kim, Sang-Hee Lee, Jin Man Kim, Gi Ryang Kweon, Ki Cheol Park, Jung Uee Lee, Yo
PLoS Genetics.2013; 9(3): e1003356. CrossRef
Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons
Feiyang Liu, Yijin Wang, Ming Yan, Luyong Zhang, Tao Pang, Hong Liao
Neuroscience Letters.2013; 557: 90. CrossRef
Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis
A. Cignarelli, F. Giorgino, R. Vettor
Archives of Physiology and Biochemistry.2013; 119(4): 139. CrossRef
Labisia pumilaUpregulates Peroxisome Proliferator-Activated Receptor Gamma Expression in Rat Adipose Tissues and 3T3-L1 Adipocytes
Fazliana Mansor, Harvest F. Gu, Claes-Göran Östenson, Louise Mannerås-Holm, Elisabet Stener-Victorin, Wan Nazaimoon Wan Mohamud
Advances in Pharmacological Sciences.2013; 2013: 1. CrossRef
Protocol for effective differentiation of 3T3-L1 cells to adipocytes
Katja Zebisch, Valerie Voigt, Martin Wabitsch, Matthias Brandsch
Analytical Biochemistry.2012; 425(1): 88. CrossRef

Reviews

Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy: Sungjin Chung, Cheol Whee Park; Diabetes Metab J. 2011;35(4):327-336. Published online August 31, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.4.327

65,535 View
54 Download
20 Crossref

Abstract PDF PubReader

With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.

Citations

Citations to this article as recorded by

Coriander microgreens and baby greens: Comparison of volatile and non-volatile metabolites and potential therapeutic effects on type 2 diabetes mellitus and obesity
Yuan Zhong, Yuxuan Xie, Jian Lyu, Yandong Xie, Cai Zhao, Jihua Yu
Food Research International.2025; 202: 115759. CrossRef
Oxidative stress, inflammation, and steatosis elucidate the complex dynamics of HgCl2 induced liver damage in Channa punctata
Shefalee Singh, Shikha Dwivedi, Adeel Ahmad Khan, Anamika Jain, Shraddha Dwivedi, Kamlesh Kumar Yadav, Indrani Dubey, Abha Trivedi, Sunil P. Trivedi, Manoj Kumar
Scientific Reports.2024;[Epub] CrossRef
Ethyl Acetate Fractions of Salvia miltiorrhiza Bunge (Danshen) Crude Extract Modulate Fibrotic Signals to Ameliorate Diabetic Kidney Injury
Yung-Chien Hsu, Ya-Hsueh Shih, Cheng Ho, Cheng-Chi Liu, Chia-Ching Liaw, Hui-Yi Lin, Chun-Liang Lin
International Journal of Molecular Sciences.2024; 25(16): 8986. CrossRef
Peroxisome Proliferator-Activated Receptor Alpha Stimulation Preserves Renal Tight Junction Components in a Rat Model of Early-Stage Diabetic Nephropathy
Lorena Rosas-Martínez, Rafael Rodríguez-Muñoz, María del Carmen Namorado-Tonix, Fanis Missirlis, Leonardo del Valle-Mondragón, Alicia Sánchez-Mendoza, José L. Reyes-Sánchez, Luz Graciela Cervantes-Pérez
International Journal of Molecular Sciences.2024; 25(23): 13152. CrossRef
The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension
Akram Abolbaghaei, Maddison Turner, Jean-François Thibodeau, Chet E. Holterman, Christopher R. J. Kennedy, Dylan Burger
International Journal of Molecular Sciences.2023; 24(5): 4930. CrossRef
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway
Laongdao Thongnak, Nattavadee Pengrattanachot, Sasivimon Promsan, Nichakorn Phengpol, Prempree Sutthasupha, Krit Jaikumkao, Anusorn Lungkaphin
Archives of Pharmacal Research.2023; 46(5): 408. CrossRef
A comprehensive insight into the molecular and cellular mechanisms of the effects of Propolis on preserving renal function: a systematic review
Paniz Anvarifard, Maryam Anbari, Alireza Ostadrahimi, Mohammadreza Ardalan, Zohreh Ghoreishi
Nutrition & Metabolism.2022;[Epub] CrossRef
APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice
Eun Soo Lee, Hong Min Kim, Sun Hee Lee, Kyung Bong Ha, Yoon Soo Bae, Soo Jin Lee, Sung Hwan Moon, Eun Young Lee, Ji-Hye Lee, Choon Hee Chung
Free Radical Biology and Medicine.2020; 161: 92. CrossRef
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
Xiaomeng Sun, Jia Liu, Guang Wang
Lipids in Health and Disease.2020;[Epub] CrossRef
AMPK allostery: A therapeutic target for the management/treatment of diabetic nephropathy
Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba, Boyenle Ibrahim, Du Lei, Qian Lu, Xiaoxing Yin, Temitope Isaac Adelusi
Life Sciences.2020; 261: 118455. CrossRef
Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor
Ravi Shankar Singh, Dharmendra Kumar Chaudhary, Aradhana Mohan, Praveen Kumar, Chandra Prakash Chaturvedi, Carolyn M. Ecelbarger, Madan M. Godbole, Swasti Tiwari
Scientific Reports.2016;[Epub] CrossRef
Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury
Yong Yang, Ting Bai, You-Li Yao, De-Quan Zhang, Yan-Ling Wu, Li-Hua Lian, Ji-Xing Nan
Toxicology Letters.2016; 262: 80. CrossRef
Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan
Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J. Gonzalez, Toshifumi Aoyama
Clinical Science.2016; 130(21): 1969. CrossRef
Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice
Eun Sil Koh, Ji Hee Lim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Bum Soon Choi, Hye Won Kim, Seong Yeon Hwang, Sae Woong Kim, Cheol Whee Park, Yoon Sik Chang
Journal of Translational Medicine.2015;[Epub] CrossRef
Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives
Cheol Whee Park
Diabetes & Metabolism Journal.2014; 38(4): 252. CrossRef
Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
Marijn M. Speeckaert, Céline Vanfraechem, Reinhart Speeckaert, Joris R. Delanghe
Ageing Research Reviews.2014; 14: 1. CrossRef
Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats
Pitchai Balakumar, Rajavel Varatharajan, Ying Hui Nyo, Raja Renushia, Devarajan Raaginey, Ann Nah Oh, Shaikh Sohrab Akhtar, Mani Rupeshkumar, Karupiah Sundram, Sokkalingam A. Dhanaraj
Pharmacological Research.2014; 90: 36. CrossRef
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
Supriya Kadian, Nanjaian Mahadevan, Pitchai Balakumar
European Journal of Pharmacology.2013; 698(1-3): 388. CrossRef
Age-Associated Molecular Changes in the Kidney in Aged Mice
Ji Hee Lim, Eun Nim Kim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Hyung Wook Kim, Chul Woo Yang, Yong-Soo Kim, Yoon Sik Chang, Cheol Whee Park, Bum Soon Choi
Oxidative Medicine and Cellular Longevity.2012; 2012: 1. CrossRef
Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease
Rikki M. Tanner, Todd M. Brown, Paul Muntner
Current Hypertension Reports.2012; 14(2): 152. CrossRef

Diabetes and Osteoporosis.: Ki Won Oh; Korean Diabetes J. 2009;33(3):169-177. Published online June 1, 2009; DOI: https://doi.org/10.4093/kdj.2009.33.3.169

2,673 View
34 Download
8 Crossref

Abstract PDF

Increased life expectancy and increased obesity have contributed to an increasing incidence of osteoporosis and diabetes mellitus. Recent meta-analyses and cohort studies confirm that diabetes is associated with a higher risk of fracture. Patients with type 2 diabetes exhibit increased fracture risks despite a higher bone mass, which are mainly attributable to non-skeletal risk factors. Patients with type 1 diabetes may have impaired bone formation because of absence of the anabolic effects of insulin and insulin-like growth factor I (IGF-I) system. Several clinical studies have reported adverse skeletal actions of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist in humans. Obesity regulates bone metabolism not only by increasing weight loading but also by modulating adipokines that are known to affect bone remodeling.

Citations

Citations to this article as recorded by

CTX-1 and TRACP-5b as biomarkers for osteoporosis risk in type 2 diabetes mellitus: a cross-sectional study
Madhura Roy, Haya Majid, Parvej Khan, Nikhil Sharma, Sunil Kohli, Sajad Ul Islam, Divya Vohora, Nidhi
Journal of Diabetes & Metabolic Disorders.2024; 23(2): 2055. CrossRef
Relationship between hs-CRP and HbA1c in Diabetes Mellitus Patients: 2015–2017 Korean National Health and Nutrition Examination Survey
Yo-Han Seo, Hee-Young Shin
Chonnam Medical Journal.2021; 57(1): 62. CrossRef
Correlation between Serum Osteocalcin and Hemoglobin A1c in Gwangju General Hospital Patients
Yo-Han Seo, Hee-Young Shin
The Korean Journal of Clinical Laboratory Science.2018; 50(3): 313. CrossRef
Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice
Xue-Ju Li, Zhe Zhu, Si-Lin Han, Zi-Long Zhang
International Journal of Molecular Medicine.2016; 38(6): 1661. CrossRef
The association of Osteoporosis and Thyroid Hormone in euthyroid adults
Hyun Yoon, Eun-Jin Ryu
Journal of the Korea Academia-Industrial cooperation Society.2015; 16(2): 1137. CrossRef
A Study on the Correlation between Menopausal Rating Scale and Bone Mineral Density for Menopausal Osteoporosis Patients※
Kyu In Kwak, Jae Hui Kang, Yun Joo Kim, Hyun Lee
The Acupuncture.2014; 31(3): 25. CrossRef
Factors Associated with Bone Mineral Density in Korean Postmenopausal Women Aged 50 Years and Above: Using 2008-2010 Korean National Health and Nutrition Examination Survey
Son-Ok Mun, Jihye Kim, Yoon Jung Yang
Korean Journal of Community Nutrition.2013; 18(2): 177. CrossRef
Influencing Factors of Bone Mineral Density in Men
Dong-Ha Lee, Eun-Nam Lee
Journal of muscle and joint health.2011; 18(1): 5. CrossRef

Original Articles

Association Study of the Peroxisome Proliferators-Activated Receptor gamma2 Pro12Ala Polymorphism with Diabetic Nephropathy.: Kyu Ho Lee, Hee Seog Jeong, Khan Young Choi, Hyun Kim, Dal Sic Lee, Ji Young Kang, Hyun Jeong Jeon, Tae Keun Oh; Korean Diabetes J. 2008;32(5):402-408. Published online October 1, 2008; DOI: https://doi.org/10.4093/kdj.2008.32.5.402

2,340 View
27 Download

Abstract PDF: BACKGROUND
Peroxisome proliferators-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and known to play a role in regulating the expression of numerous genes involved in lipid metabolism, metabolic syndrome, inflammation, and atherosclerosis. The PPARgamma2 Pro12Ala polymorphism has recently been shown to be associated with diabetic nephropathy. In this study, we evaluated the relationship between PPARgamma2 Pro12Ala polymorphism and type 2 diabetic nephropathy whose duration of diabetes was over 10 years. METHODS: We conducted a case-control study, which enrolled 367 patients with type 2 diabetes. Genotyping of PPARgamma2 Pro12Ala polymorphism was performed using polymerase chain reaction followed by digestion with Hae III restriction enzyme. RESULTS: The genotype or allele frequencies of PPARgamma2 Pro12Ala polymorphism were not significantly different in diabetic patients with or without diabetic nephropathy. The genotype frequencies in terms of diabetic retinopathy and macrovascular complications such as coronary artery disease or stroke were not different either. Interestingly, nephropathy patients with Ala/Pro genotype showed lower C-peptide levels than those of Pro/Pro genotype. CONCLUSION: Our results suggest that PPARgamma2 Pro12Ala polymorphism is not associated with diabetic nephropathy in type 2 diabetic patients.

Association of Kir6.2 and Peroxisome Proliferator-activated Receptor-gamma (PPARgamma) Polymorphisms with Type 2 Diabetes in Koreans.: Jung Eun Lee, Su Won Kim, Hyun Ae Seo, Jae Han Jeon, Seong Su Moon, Hee Kyung Kim, Yun Jeong Doh, Bo Wan Kim, Jung Guk Kim, Min Yoo, In Kyu Lee; Korean Diabetes J. 2007;31(6):455-464. Published online November 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.6.455

2,702 View
20 Download

Abstract PDF: BACKGROUND
The type 2 diabetes is a typical polygenic disease complex, for which several common risk alleles have been identified. Several variants may contribute significantly to the risk of type 2 diabetes conferring insulin resistance of liver, muscle and fat (Pro12Ala) and a relative insulin secretory deficiency (Glu23Lys). In this study, we evaluated the association of Pro12Ala variant of the peroxisome proliferator- activated receptor-gamma and the Glu23Lys variant of the ATP-sensitive potassium channel, Kir6.2 (KCNJ11) with the type 2 diabetes in Korean population. METHOD: This study included 331 subjects consisting of 172 patients with type 2 diabetes and 159 non- diabetic control subjects enrolled from the Kyungpook, Keimyung and Catholic university hospital in Daegu, Korea. We genotyped Kir6.2 (Glu23Lys) and PPARgamma (Pro12Ala) polymorphism and examined their association with the type 2 diabetes. RESULT: In the separate analyses, the Kir6.2 Glu23Lys (P = 0.385) and the PPARgamma Pro12Ala (P = 0.191) polymorphism showed no significant association with type 2 diabetes. In addition, the results of our study showed no evidence of a synergistic interaction between Kir6.2 and PPARgamma gene in each group (P = 0.110, P = 0.276). CONCLUSION: In this study, no association was seen between the genetic polymorphisms of Kir6.2, PPARgamma and type 2 diabetes. However, to clarify whether genetic polymorphisms of these genes contribute to the development of type 2 diabetes, further studies involving larger Korean populations may be needed.

AICAR Reversed the Glucolipotoxicity Induced beta-cell Dysfunction through Suppression of PPAR-gamma-coactivator-1 (PGC-1) Overexpression.: Hyuk Sang Kwon, Ji Won Kim, Heon Seok Park, Seung Hyun Ko, Bong Yun Cha, Ho Young Son, Kun Ho Yoon; Korean Diabetes J. 2007;31(4):310-318. Published online July 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.4.310

2,434 View
25 Download

Abstract PDF: BACKGROUND
Glucolipotoxicity plays an important role in the progression of type 2 diabetes mellitus via inducing insulin secretory dysfunction. Expression of insulin gene in pancreatic beta cell might be regulated by AMP-activated protein kinase (AMPK), which is recognized as a key molecule of energy metabolism. We studied the effects of AMPK on glucolipotoxicity-induced beta-cell dysfunction by suppression of PPAR-gamma-coactivator-1 (PGC-1) in vitro and in vivo. Method: Glucolipotoxicity was induced by 33.3 mM glucose and 0.6 mM (palmitate and oleate) for 3 days in isolated rat islets. Messenger RNA (mRNA) expressions of beta-cell specific gene like insulin, BETA2/NeuroD and PGC-1 induced by glucolipotoxic condition and their changes with 5-aminoimidazole-4-carboxy-amide-1-D-ribofuranoside (AICAR) treatment were investigated using RT-PCR. We also examined glucose stimulated insulin secretion in same conditions. Furthermore, SD rats were submitted to a 90% partial pancreatectomy (Px) and randomized into two groups; Ad-GFP-infected Px rats (n = 3) and Ad-siPGC- 1-infected Px rats (n = 3). Then, the Px rats were infected with Ad-GFP or Ad-siPGC-1 (1 x 10(9) pfu) via celiac artery. After 12 days of viral infection, we measured body weight and performed the intraperitoneal glucose tolerance test (IP-GTT). RESULTS: Glucolipotoxicity resulted in blunting of glucose-stimulated insulin secretion, which was recovered by the AICAR treatment in vitro. Suppression in their expressions of insulin and BETA2/NeuroD gene by glucolipotoxic condition were improved with AICAR treatment. However, PGC-1alpha expression was gradually increased by glucolipotoxicity, and suppressed by AICAR treatment. Overexpression of PGC-1 using an adenoviral vector in freshly isolated rat islets suppressed insulin gene expression. We also confirmed the function of PGC-1 using an Ad-siPGC-1 in vivo. Direct infection of Ad-siPGC-1 in 90% pancreatectomized rats significantly improved glucose tolerance and increased body weight. CONCLUSION: AMPK could protect against glucolipotoxicity induced beta-cell dysfunction and the suppression of PGC-1 gene expression might involved in the insulin regulatory mechanism by AMPK.

Prevention of Diabetes by Fenofibrate in OLETF Rats: Hepatic Mechanism for Reducing Visceral Adiposity.: Hye Jeong Lee, Mi Kyoung Park, Kyung Il Lee, Young Jun An, Ji Min Kim, Ja Young Park, Young Han, Sook Hee Hong, Sun Seob Choi, Young Hyun Yoo, Joon Duk Suh, Duk Kyu Kim; Korean Diabetes J. 2007;31(1):63-74. Published online January 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.1.63

2,785 View
20 Download
4 Crossref

Abstract PDF

BACKGROUND
The aim of this study is to evaluate the hepatic mechanism of fenofibrate that has the diabetes protective action in rats. METHODS: We chose OLETF rats and divided them into three groups. Fenofibrate (DF) group was fed with diet and fenofibrate (300 mg/kg/day). Paired feeding (Dd) group and free diet (DD) group were fed with diet. After 36 weeks of treatment, all the rats were sacrificed. RESULTS: The fasting blood glucose level of DF group (8.5 +/- 0.9 mmol/L) showed normal. The fasting blood glucose level of Dd group (22.4 +/- 3.0 mmol/L) and DD group (16.9 +/- 3.7 mmol/L) showed significantly increased than that of DF group (P < 0.01, respectively). The body weight, visceral adipose tissue and subcutaneous adipose tissue of DF group were significantly decreased compared to those of Dd and DD groups (P < 0.01, P < 0.05, P < 0.05). DF group showed significantly increased state-3 respiration rate, ATP synthetic activity, state-4 respiration rate and their blood beta-keton body levels than those of control groups (P < 0.01, respectively). DF group showed normal morphology of hepatocytes but DD and Dd groups showed hepatic steatosis with mitochondrial swellings. CONCLUSION: Chronic fenofibrate treatment prevents the development of diabetes in OLETF rats with inhibiting gain of body weight and abdominal adiposity. The hepatic mechanism for reducing visceral adiposity is that fenofibrate leads to increasing oxidative phosphorylation, uncoupling and ketogenesis as well as increasing beta-oxidation of fatty acids. Moreover, fenofibrate treatment prevents the development of hepatic steatosis.

Citations

Citations to this article as recorded by

The Differences of Metabolic Syndrome Risk Factors according to Obesity and Abdominal Obesity in Elderly Korean Women
Kyung-A Shin
The Korean Journal of Clinical Laboratory Science.2016; 48(4): 304. CrossRef
Effects of Soybean and DJI Chungkukjang Powder on Blood Glucose and Serum Lipid Reduction in db/db Mice
Jae-Joon Lee, Ah-Ra Kim, Hae-Choon Chang, Hae-Ok Jung, Myung-Yul Lee
Journal of the Korean Society of Food Science and Nutrition.2012; 41(8): 1086. CrossRef
Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
BMB Reports .2010; 43(5): 337. CrossRef
Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
BMB Reports.2010; 43(5): 337. CrossRef

Effects of PPAR-alpha and-gamma Agonists on Fatty Acid Metabolism of Muscle Cells in Hyperlipidemic and Hyperglycemic Conditions.: Yong jik Lee, Zheng Shan Zhao, Soo Kyung Kim, Hae Jin Kim, Wan Sub Shim, Chul Woo Ahn, Hyun Chul Lee, Bong Soo Cha; Korean Diabetes J. 2006;30(5):324-335. Published online September 1, 2006; DOI: https://doi.org/10.4093/jkda.2006.30.5.324

2,730 View
34 Download
2 Crossref

Abstract PDF

BACKGROUND
Studies for the regulation of fatty acid metabolism are deficient relatively in skeletal muscle and heart. The investigations in pathological conditions for malonyl-CoA decarboxylase (MCD) and for the relation of MCD and PPAR-alpha.-gamma agonists are insufficient in particular. METHODS: In the current study, fully differentiated H9c2 muscle cells were exposed to pathological conditions such as hyperlipidemic (0.1 mM Palmitate) and hyperglycemic (16.5 mM Glucose) condition with 5 uM PPAR-gamma agonist (rosiglitazone) and 10 uM PPAR-alpha agonist (WY14,643) and then experiments such as MCD activity assay, MCD real-time RT-PCR, MCD reporter gene assay, MCD Western blotting, PPAR-alpha Western blotting, and palmitate oxidation test were carried out. RESULTS: Only PPAR-alpha agonist increased MCD activity. In the result of real-time RT-PCR, both PPAR-alpha and PPAR-gamma agonists elevated MCD mRNA expression in hyperlipidemic condition. MCD protein expression was decreased in hyperlipidemic condition, however, increased in rosiglitazone, or WY14,643 treated conditions. Rosiglitazone, and WY14,643 treated groups showed incresed MCD protein expression in hyperglycemic condition. Hyperlipidemic control group and PPAR-alpha.-gamma agonists treated groups presented about 3.8 times more increased palmitate oxidation level than normolipidemic control group in hyperlipidemic condition. PPAR-alpha agonist treated group showed 49% more increased palmitate oxidation rate than hyperlipidemic control group in primary cultured rat skeletal muscle cells. The amount of palmitate oxidation from differentiated H9c2 muscle cells that had overexpressed PPAR-alpha structural genes was more increased than control group. CONCLUSION: This study suggests that PPAR-alpha agonist ameliorates the defects induced by hyperlipidemic condition through the regulation of MCD. In summary, a closely reciprocal relation among PPAR-alpha agonist, MCD, and fatty acid oxidation existed distinctly in hyperlipidemic condition, but not in hyperglycemic condition.

Citations

Citations to this article as recorded by

Beneficial effect of Combination with Korean Red Ginseng and Morus alba in metabolic syndrome
Yun Jung Lee, Hye Yoom Kim, Jung Joo Yoon, So Min Lee, You Mee Ahn, Joung Hyun Kho, Min Chul Kho, Ho Sub Lee, Kyung Min Choi, Dae Gill Kang
The Korea Journal of Herbology.2012; 27(6): 99. CrossRef
Effects of Mixed Extract from Lycium chinense, Cordyceps militaris, and Acanthopanax senticosus on Glucose-Regulating Enzymes of HepG2 in Hyperglycemic Conditions
Dae-Jung Kim, Jeong-Mi Kim, Tae-Hyuk Kim, Jong-Mi Baek, Hyun-Sook Kim, Myeon Choe
Journal of the Korean Society of Food Science and Nutrition.2010; 39(9): 1257. CrossRef

Effects of Caloric Restriction on the Expression of PGC-1 and PPARs mRNA in Liver of Otsuka Long-Evans Tokushima Fatty Rats.: Sang Yong Kim, Jin Hwa Kim, Hak Yeon Bae, Byoung Rai Lee; Korean Diabetes J. 2006;30(3):161-169. Published online May 1, 2006; DOI: https://doi.org/10.4093/jkda.2006.30.3.161

2,267 View
27 Download

Abstract PDF: BACKGROUND
Gluconeogenesis is strongly stimulated during fasting and is aberrantly activated in diabetes mellitus. PPARgamma-coactivator 1 (PGC-1) and Peroxisome proliferator -activated receptors (PPARs) costimulate the expression of key enzymes of gluconeogenetic pathway. This study was performed to evaluate the response to dietary caloric restriction (CR) on the PPARs and PGC-1 expression in liver of diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. METHODS: Diabetic OLETF rats (male, 24 weeks) and Long-Evans Tokushima Otsuka (LETO) rats (male, 24 weeks) were used in this study. Liver PPARs and PGC-1 mRNA, and blood glucose levels were investigated at 1, 2, and 3 weeks after the beginning of 30% CR. PPARs and PGC-1 mRNA were determined by RT-PCR and blood glucose levels were measured by spectrophotometric assay. RESULTS: The liver PGC-1 mRNA expressions were increased to 19% in non-diabetic LETO rats but significant change was not observed in diabetic OLETF rats by 30% CR. The liver PPARgamma mRNA expressions were not changed in non-diabetic LETO rats but increased to 23% in diabetic OLETF rats by 30% CR. The difference of PPARalpha and PPARbeta mRNA expressions in liver of OLETF and LETO rats were not observed. CONCLUSION: The liver PPARgamma and PGC-1 expression response to CR are altered in OLETF rats compared to in LETO rats. These findings suggested that PPARgamma and PGC-1 expression control system altered in diabetic OLETF rat liver and altered PPARgamma and PCG-1 expression may some roles on the aberrantly activated gluconeogenesis in diabetes mellitus.

First
Prev
Page of 2
Next
Last

Search